Amicus Therapeutics (FOLD) Reports Q2 Loss of $0.34

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. MSFT
3. GOOGL
4. FTNT
5. EBAY
6. CMG
7. TENB
8. BIIB
9. KLAC
10. ETSY

Go back to Amicus Therapeutics (FOLD) Reports Q2 Loss of $0.34

Amicus Therapeutics Announces Second Quarter 2017 Financial Results and Corporate Updates

August 7, 2017 7:00 AM EDT

            179 Fabry Disease Patients on Reimbursed Galafold (migalastat) as of July 31 On Target to Reach 300 Patients by Year-End 2017

Migalastat NDA Submission Targeted for 4Q17

Phase 3 EB Topline Data and Complete Phase 1/2 Pompe Data on Track for Late 3Q17

CRANBURY, N.J., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced financial results for the second quarter ended June 30, 2017. The Company also provided... More